These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9187432)

  • 1. Is CHOP the standard of therapy for poor-prognosis large-cell lymphoma?
    Canellos GP
    Ann Oncol; 1997; 8 Suppl 1():61-2. PubMed ID: 9187432
    [No Abstract]   [Full Text] [Related]  

  • 2. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Connors JM
    Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab plus CHOP for diffuse large-B-cell lymphoma.
    Akhtar S; Maghfoor I
    N Engl J Med; 2002 Jun; 346(23):1830-1; author reply 1830-1. PubMed ID: 12050349
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
    Copson E
    Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
    [No Abstract]   [Full Text] [Related]  

  • 9. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
    Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
    [No Abstract]   [Full Text] [Related]  

  • 11. CHOP may have been part of the beginning but certainly not the end: issues in risk-related therapy of large-cell lymphoma.
    Canellos GP
    J Clin Oncol; 1997 May; 15(5):1713-6. PubMed ID: 9164176
    [No Abstract]   [Full Text] [Related]  

  • 12. FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP).
    Camilleri-Broët S; Mounier N; Delmer A; Brière J; Casasnovas O; Cassard L; Gaulard P; Christian B; Coiffier B; Sautès-Fridman C
    Leukemia; 2004 Dec; 18(12):2038-40. PubMed ID: 15470484
    [No Abstract]   [Full Text] [Related]  

  • 13. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
    Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP and rituximab in elderly patients.
    Portlock CS
    Curr Oncol Rep; 2002 Sep; 4(5):414. PubMed ID: 12162916
    [No Abstract]   [Full Text] [Related]  

  • 15. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age.
    Takasaki H; Hashimoto C; Fujita A; Matsumoto K; Taguchi J; Kuwabara H; Yamazaki E; Koharazawa H; Fujita H; Fujisawa S; Ishii Y; Yamamoto W; Motomura S; Tomita N; Ishigatsubo Y; Sakai R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):404-9. PubMed ID: 23763919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to editorial by Dr. Earle.
    Fuller LM
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):435-6. PubMed ID: 7530703
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapy of diffuse large B-cell lymphomas.
    Pfreundschuh M
    Eur J Cancer; 2009 Sep; 45 Suppl 1():386-7. PubMed ID: 19775641
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma.
    Burke HB
    N Engl J Med; 1995 Sep; 333(11):728; author reply 730. PubMed ID: 7637756
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 20. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.